---
figid: PMC2571037__JCI0837553.f1
figlink: /pmc/articles/PMC2571037/figure/F1/
number: Figure 1
caption: In healthy cells, mitogenic growth factors signaling through the MAPK pathway
  trigger sequential phosphorylation and activation of MEK and ERK kinases, which
  in turn leads to stabilization of Mcl-1, activation of Bcl-2, and degradation of
  Bim, thereby promoting cell survival. In tumors with B-RAF mutations, B-Raf causes
  pathway activation independent of upstream signaling by either directly activating
  MEK1/2 or activating c-Raf, depending on the B-Raf variant present. In this issue
  of the JCI, Cragg et al. show that MEK inhibitors such as U0126, PD098059, and PD325901
  upregulate Bim but do not induce regressions of tumors harboring B-RAF mutations
  (). The authors also propose that Bcl-2 and Bcl-xL neutralize the increased Bim,
  thereby diminishing the potential apoptotic effect of the MEK inhibitors. Consistent
  with this model, the authors show that addition of the Bcl-2/Bcl-xL antagonist ABT-737
  enhances the apoptotic effect of MEK inhibition. When Bcl-2 and Bcl-xL are antagonized,
  the upregulated Bim binds to Mcl-1, causing it to release Bak and/or Bax, leading
  to cytochrome c release and subsequent apoptosis. Because tumors with B-RAF mutations
  are dependent on the MAPK pathway rather than the Akt pathway for survival, combining
  a MEK inhibitor and a Bcl-2/Bcl-xL antagonist appears to be a promising strategy
  for treating these tumors. c-FLIP, cellular FLICE (caspase 8) inhibitory protein;
  Grb, growth factor receptor–bound protein 2; GSK, glycogen synthase kinase; mTOR,
  mammalian target of rapamycin; PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin
  homology domain; PIP2, phosphoinositol-4,5-bisphosphate; PIP3, phosphoinositol-3,4,5-trisphosphate;
  PTEN, phosphatase and tensin homolog; SOS, son of sevenless; XIAP, X-linked inhibitor
  of apoptosis protein.
pmcid: PMC2571037
papertitle: 'Anticancer therapy: boosting the bang of Bim.'
reftext: Andrea Wahner Hendrickson, et al. J Clin Invest. 2008 Nov 3;118(11):3582-3584.
pmc_ranked_result_index: '137433'
pathway_score: 0.9219228
filename: JCI0837553.f1.jpg
figtitle: 'Anticancer therapy: boosting the bang of Bim'
year: '2008'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2571037__JCI0837553.f1.html
  '@type': Dataset
  description: In healthy cells, mitogenic growth factors signaling through the MAPK
    pathway trigger sequential phosphorylation and activation of MEK and ERK kinases,
    which in turn leads to stabilization of Mcl-1, activation of Bcl-2, and degradation
    of Bim, thereby promoting cell survival. In tumors with B-RAF mutations, B-Raf
    causes pathway activation independent of upstream signaling by either directly
    activating MEK1/2 or activating c-Raf, depending on the B-Raf variant present.
    In this issue of the JCI, Cragg et al. show that MEK inhibitors such as U0126,
    PD098059, and PD325901 upregulate Bim but do not induce regressions of tumors
    harboring B-RAF mutations (). The authors also propose that Bcl-2 and Bcl-xL neutralize
    the increased Bim, thereby diminishing the potential apoptotic effect of the MEK
    inhibitors. Consistent with this model, the authors show that addition of the
    Bcl-2/Bcl-xL antagonist ABT-737 enhances the apoptotic effect of MEK inhibition.
    When Bcl-2 and Bcl-xL are antagonized, the upregulated Bim binds to Mcl-1, causing
    it to release Bak and/or Bax, leading to cytochrome c release and subsequent apoptosis.
    Because tumors with B-RAF mutations are dependent on the MAPK pathway rather than
    the Akt pathway for survival, combining a MEK inhibitor and a Bcl-2/Bcl-xL antagonist
    appears to be a promising strategy for treating these tumors. c-FLIP, cellular
    FLICE (caspase 8) inhibitory protein; Grb, growth factor receptor–bound protein
    2; GSK, glycogen synthase kinase; mTOR, mammalian target of rapamycin; PDK1, phosphoinositide-dependent
    kinase 1; PH, pleckstrin homology domain; PIP2, phosphoinositol-4,5-bisphosphate;
    PIP3, phosphoinositol-3,4,5-trisphosphate; PTEN, phosphatase and tensin homolog;
    SOS, son of sevenless; XIAP, X-linked inhibitor of apoptosis protein.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - BCL2L11
  - BCL2
  - MAPK11
  - MAPK9
  - PTEN
  - BCL2L1
  - CFLAR
  - NFKB1
  - MAPK8
  - BAK1
  - XIAP
  - MAPK3
  - MAP2K2
  - PDK1
  - BAD
  - FOXO1
  - FOXO3
  - MAP2K1
  - MTOR
  - SOS2
  - MAPK1
  - FOXO6
  - FASLG
  - AKT2
  - RAF1
  - MAPK14
  - AKT1
  - MAPK13
  - FOXO4
  - NRAS
  - SOS1
  - HRAS
  - MCL1
  - AKT3
  - MAPK10
  - MAPK12
  - KRAS
  - PD098059
  - U0126
  - ABT-737
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: B-Raf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Bim
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
- word: Bcl-2/
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: Bcl-x
  symbol: Bcl-X
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L1
  entrez: '598'
- word: c-FLIP
  symbol: c-FLIP
  source: hgnc_alias_symbol
  hgnc_symbol: CFLAR
  entrez: '8837'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: Bak
  symbol: BAK
  source: hgnc_alias_symbol
  hgnc_symbol: BAK1
  entrez: '578'
- word: XIAP,
  symbol: XIAP
  source: hgnc_symbol
  hgnc_symbol: XIAP
  entrez: '331'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: FoxoЗа
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: FoxoЗа
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FoxoЗа
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: Fasl
  symbol: FasL
  source: hgnc_alias_symbol
  hgnc_symbol: FASLG
  entrez: '356'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: c-Raf
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: FoxoЗа
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Mcl-1
  symbol: Mcl-1
  source: hgnc_alias_symbol
  hgnc_symbol: MCL1
  entrez: '4170'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: PD098059
  source: MESH
  identifier: C093973
- word: U0126
  source: MESH
  identifier: C113580
- word: ABT-737
  source: MESH
  identifier: C501332
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
